Cytokinetics (NASDAQ:CYTK) Raised to “Hold” at Wall Street Zen

Cytokinetics (NASDAQ:CYTK) was upgraded by stock analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a note issued to investors on Monday, Wall Street Zen reports.

Other research analysts also recently issued reports about the stock. Citizens Jmp boosted their price objective on shares of Cytokinetics from $105.00 to $110.00 and gave the company a “market outperform” rating in a research report on Friday, August 7th. Citigroup reaffirmed a “market outperform” rating on shares of Cytokinetics in a research report on Friday, August 7th. Morgan Stanley raised shares of Cytokinetics from an “overweight” rating to a “buy” rating in a research report on Tuesday, September 1st. HC Wainwright reaffirmed a “buy” rating and set a $140.00 target price on shares of Cytokinetics in a research note on Monday, August 31st. Finally, Mizuho boosted their price target on shares of Cytokinetics from $100.00 to $118.00 and gave the company an “outperform” rating in a research report on Wednesday, June 24th. Eighteen equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $106.06.

Cytokinetics Stock Performance

CYTK opened at $61.62 on Monday. Cytokinetics has a 52-week low of $54.30 and a 52-week high of $88.31. The stock has a market capitalization of $7.67 billion, a PE ratio of -8.53 and a beta of 0.41. The stock’s 50 day moving average price is $71.13 and its 200-day moving average price is $73.27.

Cytokinetics (NASDAQ:CYTK) last announced its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($1.50) EPS for the quarter, beating analysts’ consensus estimates of ($1.63) by $0.13. The business had revenue of $28.62 million for the quarter, compared to the consensus estimate of $17.59 million. During the same quarter in the prior year, the company earned ($1.12) EPS. Cytokinetics’s revenue was down 57.1% compared to the same quarter last year. Research analysts forecast that Cytokinetics will post -5.98 EPS for the current fiscal year.

Insider Transactions at Cytokinetics

In related news, EVP Fady Malik sold 3,500 shares of the company’s stock in a transaction on Tuesday, October 6th. The stock was sold at an average price of $61.38, for a total value of $214,830.00. Following the sale, the executive vice president directly owned 153,902 shares of the company’s stock, valued at $9,446,504.76. This represents a 2.22% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Robert I. Blum sold 7,500 shares of the stock in a transaction on Monday, October 12th. The stock was sold at an average price of $62.88, for a total value of $471,600.00. Following the completion of the transaction, the chief executive officer owned 278,544 shares of the company’s stock, valued at approximately $17,514,846.72. This trade represents a 2.62% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 191,426 shares of company stock valued at $13,601,885. Company insiders own 2.60% of the company’s stock.

Institutional Trading of Cytokinetics

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Principal Financial Group Inc. lifted its position in Cytokinetics by 11.9% during the 1st quarter. Principal Financial Group Inc. now owns 1,093,485 shares of the biopharmaceutical company’s stock valued at $72,072,000 after acquiring an additional 116,593 shares during the period. ADAR1 Capital Management LLC grew its holdings in Cytokinetics by 17.1% in the first quarter. ADAR1 Capital Management LLC now owns 632,556 shares of the biopharmaceutical company’s stock worth $41,692,000 after purchasing an additional 92,390 shares during the period. Siren L.L.C. purchased a new stake in Cytokinetics in the first quarter worth about $40,466,000. Handelsbanken Fonder AB grew its holdings in Cytokinetics by 63.8% in the second quarter. Handelsbanken Fonder AB now owns 405,000 shares of the biopharmaceutical company’s stock worth $34,502,000 after purchasing an additional 157,700 shares during the period. Finally, E. Ohman J or Asset Management AB increased its stake in shares of Cytokinetics by 1.3% during the second quarter. E. Ohman J or Asset Management AB now owns 304,611 shares of the biopharmaceutical company’s stock valued at $25,950,000 after purchasing an additional 3,849 shares in the last quarter.

More Cytokinetics News

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: Additional analyses from the Phase 3 ACACIA-HCM study further characterized aficamten’s effects across exercise-performance measures and patient responder groups. The data also supported the drug’s dose-adjustment approach and safety profile, potentially strengthening Cytokinetics’ case for aficamten as a future treatment for non-obstructive HCM. Cytokinetics Announces Additional Data from ACACIA-HCM Presented at the HFSA Annual Scientific Meeting 2026
• Positive Sentiment: Several market commentaries highlighted the Phase 3 aficamten results and the possibility that the drug’s multi-domain benefits could improve Cytokinetics’ long-term commercial outlook. The company’s pipeline and potential heart-drug opportunity are driving the fresh investor interest, although regulatory and commercialization risks remain. Cytokinetics Highlights Exercise Capacity, Responder Data For Aficamten in NHCM
• Neutral Sentiment: Wall Street Zen upgraded Cytokinetics to a “Hold,” suggesting a more balanced view of the shares after the recent clinical updates rather than a clearly bullish or bearish shift. Wall Street Zen Upgrades Cytokinetics to Hold
• Neutral Sentiment: Chief Executive Officer Robert I. Blum sold 7,500 shares for approximately $471,600 under a pre-arranged Rule 10b5-1 trading plan. Because the sale was scheduled in advance and he retained 278,544 shares, it is a limited signal of insider sentiment, though it may add modest pressure to investor perception. SEC Form 4 Filing

About Cytokinetics

Cytokinetics, Incorporated is a biopharmaceutical company focused on discovering and developing medicines that improve muscle function. The company applies muscle biology and molecular pharmacology to develop therapies for cardiovascular and neuromuscular diseases in which impaired muscle performance contributes to disease progression or disability.

Its lead programs include aficamten, a next-generation cardiac myosin inhibitor being developed for hypertrophic cardiomyopathy, and other investigational compounds designed to modulate the activity of cardiac or skeletal muscle.